| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. | SVP, General Counsel | Stock Option (Right to buy) | 512,370 | $1,421,624 | $9.62 | 24 Jan 2025 | Direct |
| Allogene Therapeutics, Inc. | SVP, General Counsel | Common Stock | 587,848 | $1,005,220 | $1.71 | 03 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 03 Feb 2025 | 1 | -$10,951 | 4 | SVP, General Counsel | 05 Feb 2025, 16:16 |
| ALLO | Allogene Therapeutics, Inc. | 24 Jan 2025 | 2 | $0 | 4 | SVP, General Counsel | 28 Jan 2025, 20:16 |
| ALLO | Allogene Therapeutics, Inc. | 21 Aug 2024 | 1 | -$78,843 | 4 | SVP, General Counsel | 23 Aug 2024, 16:15 |
| ALLO | Allogene Therapeutics, Inc. | 25 Jan 2024 | 2 | $0 | 4 | SVP, General Counsel | 31 Jan 2024, 17:48 |
| ALLO | Allogene Therapeutics, Inc. | 14 Aug 2023 | 3 | $0 | 4 | GENERAL COUNSEL | 17 Aug 2023, 19:57 |
| ALLO | Allogene Therapeutics, Inc. | 14 Aug 2023 | 0 | $0 | 3 | GENERAL COUNSEL | 17 Aug 2023, 15:50 |